Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
← catalyst calendarNCT03636438 · readout ≤ 1,230 d
Sponsored by Ultragenyx Pharmaceutical Inc (industry) · RARE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
11actual
Sites
9
Countries
Canada, France, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-08-30 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ornithine Transcarbamylase (OTC) Deficiency
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events and Serious Adverse Events
measured Up to 416 weeks
Permalink · RARE's whole pipeline · Catalyst calendar · Every registered study · What changed